Targeting HIF‐2α in renal cell carcinoma: Expanding upon belzutifan
Cancer · 01.02.2026 · 132 (3)
DOI: 10.1002/cncr.70239 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 03.02.2026. Verfasst von Melanie Rodriguez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Basic Helix-Loop-Helix Proteins, Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Welch Foundation.
Abstract (Originalsprache)
Background
Clear cell renal cell carcinoma (ccRCC) is a common subtype of kidney cancer driven by the inactivation of the von Hippel‐Lindau ( VHL ) gene, leading to the accumulation of hypoxia‐inducible factor (HIF)‐2α and tumorigenesis.
Methods
Targeting HIF‐2α has emerged as a promising therapeutic strategy culminating in the development of a first‐in‐class inhibitor, belzutifan, invented by Peloton Therapeutics and marketed by Merck. This article presents the journey to belzutifan and subsequent developments.
Results
We discuss the structure‐based design leading to the first‐in‐human drug, PT2385, as well as subsequent modifications to improve pharmacokinetic properties leading to PT2977/belzutifan. Detailed analyses are presented of key HIF‐2α structural features, the mechanism of drug action, and how this family of drugs performed in preclinical models. Belzutifan’s impact on patients with VHL syndrome, sporadic advanced ccRCC and pheochromocytoma/paraganglioma is discussed, three areas where belzutifan has obtained Food and Drug Administration approval. Drug combination strategies, mechanisms of resistance, and emerging strategies to overcome them, including siRNA‐based therapeutics, are presented. Alternative HIF‐2α inhibitors are examined, including NKT2152 and AB521.
Conclusions
By expanding upon the foundation established by belzutifan, the field is poised for further therapeutic advances.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA.
- Department of Internal Medicine, Division of Hematology-Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA.
- Kidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
ORCID-Profile: Melanie Rodriguez, Uttam K Tambar
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- Welch Foundation
- National Institute of General Medical Sciences
- National Cancer Institute
Zitieren
APA
Rodriguez, M., Qin, Q., Tambar, U. K., & Brugarolas, J. (2026). Targeting HIF‐2α in renal cell carcinoma: Expanding upon belzutifan. Cancer, 132(3). https://doi.org/10.1002/cncr.70239
Vancouver
Rodriguez M, Qin Q, Tambar UK, Brugarolas J. Targeting HIF‐2α in renal cell carcinoma: Expanding upon belzutifan. Cancer. 2026;132(3). doi:10.1002/cncr.70239
BibTeX
@article{Rodriguez2026,
author = {Rodriguez, Melanie and Qin, Qian and Tambar, Uttam K and Brugarolas, James},
title = {Targeting HIF‐2α in renal cell carcinoma: Expanding upon belzutifan},
journal = {Cancer},
year = {2026},
volume = {132},
number = {3},
doi = {10.1002/cncr.70239}
}
EUVIMED